Quarterly report · Q2
6095.TEDINET S100TEBI
Period2023-10-01 → 2024-03-31
Filed2024-05-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥7.9bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥14.5bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.1bn | 2022-10-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥836m | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥717m | 2022-10-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥831m | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥735m | 2022-10-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥550m | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥735m | 2022-10-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥199m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥618m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥380m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥213m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥391m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥14.9bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥15.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥14.5bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.2bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥6.6bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥8.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.4bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.1bn | at 2022-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥807m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥600m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥122m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥47m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.0bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.8bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥378m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.7bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥4.2bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥9.18 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.16 | 2024-01-01 → 2024-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.33 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.42 | 2022-10-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.03 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.99 | 2022-10-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥17.05 | 2022-10-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 56.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2024-03-31 | −¥434,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2024-03-31 | −¥434,000 |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-03-31 | −¥685m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥6.4bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥6.4bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥15,000 |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥1.5bn |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | −¥131m |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥419,000 |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥153m |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥7.9bn |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥7.9bn |
| —segment total | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥434,000 |
| —segment total | segment profit | 2023-10-01 → 2024-03-31 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2022-10-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-10-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2023-03-31 | −¥657m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥5.7bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥5.7bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥243m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥240m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥3m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | −¥40m |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥300,000 |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | ¥94m |
| —segment total | revenue | 2022-10-01 → 2023-03-31 | ¥7.1bn |
| —segment total | revenue external | 2022-10-01 → 2023-03-31 | ¥7.1bn |
| —segment total | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥5m |
| —segment total | segment profit | 2022-10-01 → 2023-03-31 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 519
| Item | Context | Value | Unit |
|---|---|---|---|
| Profit loss | Prior1YTDDuration | 390644000 | JPY |
| Profit loss | CurrentYTDDuration | 213455000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | -647000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | -379000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | － | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | -423000 | JPY |
| Other comprehensive income | Prior1YTDDuration | -647000 | JPY |
| Other comprehensive income | CurrentYTDDuration | -803000 | JPY |
| Comprehensive income | Prior1YTDDuration | 389997000 | JPY |
| Comprehensive income | CurrentYTDDuration | 212652000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 379764000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 198475000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 10233000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | 14177000 | JPY |
| Income before income taxes | Prior1YTDDuration | 735082000 | JPY |
| Income before income taxes | CurrentYTDDuration | 549755000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 69493000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 153029000 | JPY |
| Loss on retirement of noncurrent assets ope cf | Prior1YTDDuration | 54000 | JPY |
| Loss on retirement of noncurrent assets ope cf | CurrentYTDDuration | 10621000 | JPY |
| Impairment loss ope cf | Prior1YTDDuration | － | JPY |
| Impairment loss ope cf | CurrentYTDDuration | 281519000 | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 283721000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 154743000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | -85457000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | -7705000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | -766000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | － | JPY |
| Increase decrease in provision for directors bonuses ope cf | Prior1YTDDuration | -14701000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | CurrentYTDDuration | -8865000 | JPY |
| Increase decrease in provision for point card certificates ope cf | Prior1YTDDuration | -8183000 | JPY |
| Increase decrease in provision for point card certificates ope cf | CurrentYTDDuration | -77660000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -699000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -675000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 6845000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 6208000 | JPY |
| Equity in earnings losses of affiliates ope cf | Prior1YTDDuration | -26219000 | JPY |
| Equity in earnings losses of affiliates ope cf | CurrentYTDDuration | -27815000 | JPY |
| Increase decrease in trade receivables and contract assets ope cf | Prior1YTDDuration | -402453000 | JPY |
| Increase decrease in trade receivables and contract assets ope cf | CurrentYTDDuration | 17803000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | 5548000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -1798000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 20706000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | 27707000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1YTDDuration | -18077000 | JPY |
| Increase decrease in accounts payable other ope cf | CurrentYTDDuration | -166270000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | Prior1YTDDuration | -142559000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | CurrentYTDDuration | -48414000 | JPY |
| Other net ope cf | Prior1YTDDuration | -74656000 | JPY |
| Other net ope cf | CurrentYTDDuration | 183773000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |